Vir Biotechnology（VIR）财报后持续上涨，Seeking Alpha 报道当日再涨9%——无新增催化

Shares of Vir Biotechnology (VIR), a clinical-stage biopharmaceutical company focused on infectious diseases and oncology, climbed almost 9% on Tuesday. This continued a broader upward trend that has seen the stock secure 11 gains in the previous 12 sessions.
The stock dipped in the immediate aftermath of its earnings on August 5 but has been rising ever since. On Tuesday, shares advanced 87 cents to reach $10.78. It closed at $9.11 on August 5.
{"type": "symbol-chart", "props": {"ticker": "VIR"}, "data": [{"symbol": {"id": 600153, "slug": "vir", "name": "VIR", "company": "Vir Biotechnology, Inc.", "company_name": "Vir Biotechnology, Inc.", "equity_type": "stocks", "fund_type_id": 0, "followers_count": 11249, "div_yield_type": "forward", "index_group": null, "is_bdc": false, "is_reit": false, "is_currency": false, "is_crypto": false, "is_mutual_funds": false, "is_etf": false, "is_cef": false, "is_index": false, "is_bond": false, "is_commodity": false}, "prices": {"id": 600153, "last": 10.8, "change": 0.8900000000000006, "percent_change": 8.98083, "last_time": "2026-08-25T14:56:11.000-04:00", "high": 11.27, "low": 9.99, "open": 10.0, "prev_close": 9.91, "volume": 1905171.822705}, "ratings": {"quant_rating": 2.774672187715666, "sell_side_rating": 4.7, "authors_rating": 4.0}, "key_data": {"last_close_price_earnings_ratio": null, "div_rate_fwd": null, "div_rate_ttm": null, "div_yield_fwd": null, "dividend_yield": null, "short_interest_shares_outstanding": 11.25201737769909, "marketcap": 1676930200.0, "impliedmarketcap": null, "estimate_eps": -1.7795, "diluted_eps_excl_extra_itmes": -1.698187, "estimate_ffo": null, "ffo_per_share_diluted": null, "pe_ratio_fwd": -5.568980050576}}]}
The stock has climbed steadily in the weeks since Vir reported Q2 results on August 5. Revenue came in at $238.94 million, beating the $222.57 million consensus estimate by $16.37 million. The result was driven largely by a $240 million upfront payment and a $75 million equity investment from Astellas, bringing cash and investments to roughly $1.01 billion as of June 30, 2026.
Non-GAAP EPS of $0.47 missed estimates by $0.43, though net income swung to $80.1 million from a net loss of $111.0 million in the prior-year period. Shares rose 10% after-hours following that report. Read more
On the pipeline front, management noted that enrollment across all three registrational ECLIPSE studies has been completed, with top-line data from ECLIPSE 1 expected in Q4 2026 and ECLIPSE 2 and 3 readouts targeted for Q1 2027. CEO Marianne De Backer described the company as "entering a catalyst-rich period." Read more
The table below showcases the stock's daily activity over the past few days:
{"type": "table", "props": {"data": [{"date": "Aug 24, 2026", "return": "+1.33%"}, {"date": "Aug 21, 2026", "return": "+6.19%"}, {"date": "Aug 20, 2026", "return": "-5.73%"}, {"date": "Aug 19, 2026", "return": "+2.95%"}, {"date": "Aug 18, 2026", "return": "+1.06%"}, {"date": "Aug 17, 2026", "return": "+1.62%"}, {"date": "Aug 14, 2026", "return": "+2.67%"}, {"date": "Aug 13, 2026", "return": "+0.45%"}, {"date": "Aug 12, 2026", "return": "+0.34%"}, {"date": "Aug 11, 2026", "return": "+0.45%"}], "columns": [{"header": "Date", "accessor": "date", "align": "left"}, {"header": "Daily Return", "accessor": "return", "align": "right", "component": {"type": "signed-value"}}], "title": "VIR Daily Returns"}}
Biotech Beast (July 16) rated VIR a Buy, arguing the company is entering a catalyst-rich period with ECLIPSE readouts and oncology updates approaching, and noting that pro forma cash exceeded $1 billion following the Astellas deal. Read more